Finoriq research workspace
Aditxt, Inc. (ADTX) Historical Metrics
Aditxt, Inc. develops AditxtScore and FlowSpot that enable individuals to understand, manage. Review ADTX fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
- Company
- Aditxt, Inc. (ADTX)
- Ticker
- ADTX
- Market Cap
- $7,833
- Latest Price
- $0.0096
- Industry
- Biotech & Pharma
Aditxt, Inc. (ADTX) Current Valuation Metrics
Static valuation preview for Aditxt, Inc. (ADTX). Market data retrieved 2026-06-24. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 0.55x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -680,950.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -236,865.5% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.